NR4A1 and breast carcinoma: In 47 human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer, palbociclib was tested and showed a differential effect on those cell lines with an emphasize on hormone-receptor-positive and HER2-amplified ones [62].